By David Wallace
Updated September 10, 2026
The most useful questions to ask your doctor about polycythemia vera cover your diagnosis, blood count goals, symptoms, treatment choices, and what to do between visits. Bring a short written list, start with your biggest concerns, and leave with a plan you understand. Our new Polycythemia Vera Guide provides a helpful overview of PV, its blood counts, risk factors, treatment options, and long-term care.
Living with PV involves more than reviewing lab results. How you feel, what treatment asks of you, and whether you can manage everyday activities deserve a place in the conversation. You do not need medical training to describe what is happening in your own body.
Key takeaways
- Choose your three most important questions before the appointment.
- Discuss symptoms and quality of life alongside your blood counts.
- Ask why a treatment fits your situation and how you will know it is working.
- Leave knowing your next steps and whom to contact if something changes.
How to prepare for your PV appointment
Bring your medication and supplement list, recent test results from other offices, and the dates of any phlebotomies. Write down new symptoms, possible side effects, and anything you have stopped doing because you feel unwell.
Be specific. “I need to rest after showering” tells your doctor more than “I am tired.” Note when symptoms happen, how long they last, and whether they change after treatment.
Consider bringing someone to take notes. If you want to record the discussion, ask permission first.
Questions to ask your doctor about polycythemia vera
Use the sections that fit your visit. You do not need to cover every question at once.
Is my diagnosis clear?
For a first visit or second opinion, ask:
- Which findings confirm that I have PV?
- What did my JAK2 testing show, and would any additional testing change my care?
- Do I need a bone marrow biopsy? What would it tell us?
- Could another condition explain my elevated red blood cells?
PV and secondary erythrocytosis are different diagnoses. Secondary erythrocytosis means increased red blood cells caused by another condition or stimulus. It should not be described as “secondary PV.”
What are my blood count goals and clotting risks?
Hematocrit is the percentage of your blood made up of red blood cells. A treatment target below 45% is supported by the CYTO-PV trial. Your symptom experience still belongs in the discussion; a number alone cannot describe how you feel.
- What is my hematocrit target, and when should I have phlebotomy?
- How do my white blood cells and platelets affect our plan?
- What factors put me at risk for blood clots or bleeding?
- Is aspirin appropriate for me, especially if I take a blood thinner?
If you feel unwell despite reaching your target, ask what else needs evaluation. Do not assume that lowering hematocrit further is always the answer.
Is my treatment still the right fit?
The goals of PV treatment include reducing clotting risk and easing symptoms. Treatment decisions should account for your medical history and the burden of care. The MPN Cancer Connection guide explains the main treatment options in patient-friendly language.
- Why do you recommend this approach for me?
- Would medicine to reduce blood cell production be appropriate?
- What benefits, side effects, and monitoring should I expect?
- What would prompt us to change treatment?
- Could a clinical trial fit my situation?
Depending on your circumstances, discussion may include hydroxyurea, interferon treatment such as BESREMi, or Jakafi. These options are not interchangeable or appropriate for everyone.
Mimrylo (rusfertide) is another option to discuss for excess red blood cells in adults with PV. Ask how it would fit with your existing care, what monitoring it requires, and whether it could reduce your phlebotomy needs.
You can bring studies from the MPN Clinical Trial Finder to your healthcare team for an eligibility discussion.
What can we do about symptoms?
Describe fatigue, itching, concentration problems, night sweats, or abdominal fullness, even if your blood counts look reassuring. New symptoms should be assessed rather than automatically attributed to PV.
- Could this be PV, a treatment effect, or another health problem?
- Could low iron be contributing, and should we check it?
- What can we try for symptoms that interfere with daily life?
- Would a symptom questionnaire help us track changes?
Discuss iron supplements with your healthcare team before starting them. Include over-the-counter products when reviewing your medications.
Would an MPN specialist add useful guidance?
Ask whether an MPN specialist could help clarify your diagnosis or treatment choices and whether your local hematologist can coordinate care with that specialist.
You deserve explanations you understand and room to ask follow-up questions. A second opinion can be part of that process.
What should I know before leaving?
Ask for a written visit summary and confirm:
- When are my next blood tests and appointment?
- What medication changes, if any, should I make?
- Which symptoms require a call, and how do I reach someone after hours?
- Do upcoming surgery, pregnancy plans, or travel require additional planning?
- Who can help if treatment costs become difficult?
Which symptoms should not wait for an appointment?
New chest pain, sudden shortness of breath, facial drooping, one-sided weakness, or trouble speaking can signal an emergency. Call 911 or your local emergency number. New swelling, warmth, or pain in one leg also needs urgent medical assessment because it may indicate a blood clot.
A useful PV appointment ends with clearer answers and an agreed plan. Bring your priorities, speak honestly about daily life, and keep asking until you understand what happens next.
References
- Marchioli R, et al. Cardiovascular events and intensity of treatment in polycythemia vera. New England Journal of Medicine. 2013;368:22–33. doi:10.1056/NEJMoa1208500.
- MPN Cancer Connection. Polycythemia Vera Guide: Understanding PV, Treatment & Care. Accessed September 10, 2026.
- Liesveld J, Emadi A. Secondary erythrocytosis. Merck Manual Professional Edition. Updated September 2025.
- Takeda Pharmaceuticals America, Inc. Mimrylo (rusfertide) prescribing information. Revised August 2026.
- American Society of Hematology. Blood Clots. Accessed September 10, 2026.
About the Author
David Wallace is a nationally recognized myeloproliferative neoplasm (MPN) patient advocate, writer, and the founder and publisher of PV Reporter. He also founded MPN Cancer Connection, a 501(c)(3) nonprofit organization, and serves as its executive director. Diagnosed with polycythemia vera in 2009 and now in complete molecular remission, David has spent more than a decade helping patients understand MPN research, treatment options, and the questions to ask their healthcare teams. His work brings the patient voice into discussions with clinicians, researchers, and industry leaders.
Medical Disclaimer
This article is for educational purposes only and is not medical advice. It does not replace consultation with a qualified hematologist or MPN specialist. Discuss all diagnosis and treatment decisions with your healthcare team.
